Clinical Trial Update: Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating sequencing abemaciclib before 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, with recruitment ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Vadim S Koshkin | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING